Evidence map›Paper›PMID 27456204›Full record

ArticleImmunologic research2017

The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test.

M Infantino, F Meacci, V Grossi, M Manfredi, M Benucci, M Merone, P Soda

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Artificial Intelligence and Deep Learning for Rheumatologists.Arthritis & rheumatology (Hoboken, N.J.) · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

M InfantinoImmunology and Allergy Laboratory, S.Giovanni di Dio Hospital, Via Torregalli, 3, 50143, Florence, Italy. maria2.infantino@uslcentro.toscana.it.
F MeacciImmunology and Allergy Laboratory, S.Giovanni di Dio Hospital, Via Torregalli, 3, 50143, Florence, Italy.
V GrossiImmunology and Allergy Laboratory, S.Giovanni di Dio Hospital, Via Torregalli, 3, 50143, Florence, Italy.
M ManfrediImmunology and Allergy Laboratory, S.Giovanni di Dio Hospital, Via Torregalli, 3, 50143, Florence, Italy.
M BenucciRheumatology Unit, S.Giovanni di Dio Hospital, Via Torregalli, 3, 50143, Florence, Italy.
M MeroneComputer Systems & Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico, Rome, Italy.
P SodaComputer Systems & Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico, Rome, Italy.
Nuovo Ospedale San Giovanni di Dio · ITUniversità Campus Bio-Medico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the recent recommendations of the American College of Rheumatology, ANA Task Force, IIF technique should be considered the gold standard in antinuclear antibodies (ANAs) testing. To overcome the lack of standardization, biomedical industries have developed several computer-aided diagnosis (CAD) systems. Two hundred and sixty-one consecutive samples with suspected autoimmune diseases were tested for ANA by means of IIF on routinely HEp-2 assay kit (Euroimmun AG). Assignment of result was made if consensus for positive/negative was reached by at least 2 out of 3 expert physicians. ANA-IIF was also carried out using 3 CAD systems: Zenit G-Sight (n = 84), Helios (n = 85) and NOVA View (n = 92); human evaluation was repeated on the same substrate of each CAD system (Immco, Aesku and Inova HEp-2 cells, respectively). To anonymize the results, we randomly named these three systems as A, B and C. We ran a statistical analysis computing several measures of agreement between the ratings, and we also improved the evaluation by using the Wilcoxon's test for nonparametric data. Agreement between the human readings on routinely HEp-2 assay kit and human readings on CAD HEp-2 assay was substantial for A (k = 0.82) and B (k = 0.72), and almost perfect for C (k = 0.89). Such readings were statistically different only in case A. Comparing experts' readings with the readings of CAD systems, when the samples were prepared using CAD HEp-2 assay kits, we found almost perfect agreement for B and C (k = 0.86; k = 0.82) and substantial agreement for A (k = 0.73). Again, human and CAD readings were statistically different only in A. When we compared the readings of medical experts on routinely HEp-2 assay kit with the output of the CAD systems that worked using their own slides, we found substantial agreement for all the systems (A: k = 0.62; B: k = 0.65; C: k = 0.71). Such readings were not statistically different. The change of the assay kit and/or the introduction of a CAD system affect the laboratory reporting, with an evident impact on the autoimmune laboratory workflow. The CAD systems may represent one of the most important novel elements of harmonization in the autoimmunity field, reducing intra- and inter-laboratory variability in a new vision of the diagnostic autoimmune platform.

Indexed as

Biological AssayDiagnosis, Computer-AssistedAdolescentAdultAgedAged, 80 and overAntibodies, AntinuclearCell Line, TumorChildFemaleFluorescent Antibody Technique, IndirectHumansMaleMiddle AgedObserver VariationYoung AdultAntibodies, AntinuclearAntinuclear antibodiesAutomated classification systemHEp-2Indirect immunofluorescenceStandardization

Identifiers

PMID27456204
OpenAlexW2503505276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.